Paradigm gets three grants
UK company Paradigm Therapeutics has been awarded three r&d grants to carry out work on cancer, CNS diseases and hormone discovery.
It has been selected as the industrial partner in consortia that have received two three-year r&d grants under the European Commission's Framework 5 programme. The Haematopoiesis & Cancer Award has been established to broaden the knowledge of the molecular mechanisms that govern cell physiology and identify new drug targets likely to be important for the development of anti-cancer drugs. The consortium has received a grant of €2.5m (US$2.3m) for the project.
The Synaptogenet Award is to undertake research into synaptic communication in the brain with the aim of better understanding disorders such as Parkinson's Disease, depression and epilepsy. The consortium has received a grant of €1.7m ($1.6m).
Paradigm has also received a DTI Smart Award to undertake research to identify novel peptide hormones. The award will help fund the expansion of an innovative, state-of-the-art, gene identification platform that will be capable of detailed and rigorous analysis of the human genome. It will consist of a powerful cluster of computer processors running software drawn together from the most recent advances in genome and proteome analysis. Detailed information on the physiological role and, hence, the therapeutic value of these novel peptides will be determined.